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A trial of thyroxine in acute renal failure. tors, including insulin-like growth factor [4], epidermal
Background. Acute renal failure (ARF) remains a serious growth factor [5], and hepatocyte growth factor [6], have
medical problem with a high mortality rate. Efforts to shorten been shown to enhance the recovery of renal functionthe course of ARF might reduce this mortality. Since thyroxine
or to improve the survival in ischemic ARF in animals.has been shown in experimental models to shorten the course
Atrial natriuretic peptide has also been shown to beof ARF, we designed a trial to determine if a defined course
of thyroxine would alter the course or change the mortality of protective in experimental ARF [7, 8]. Several of these
clinical ARF. agents have subsequently been used in clinical trials but
Methods. A prospective, randomized, placebo-controlled, have not proved successful in altering the course of ARFdouble-blind trial of thyroxine was carried out in patients with
in patients, as they were in experimental models [9–12].ARF. End points were the percentage requiring dialysis, the
The administration of thyroid hormone following initi-percentage recovering renal function, time to recovery, and
mortality. ation of ARF has been shown to be effective in promot-
Results. Fifty-nine patients were randomized to receive either ing recovery from ARF in a wide variety of ischemic
thyroxine or placebo. The groups were well matched in terms and toxic models of ARF [13–17]. Following renal injury,of basal and entry creatinines, age, sex, APACHE II scores
thyroid hormone was administered either as a single doseat entry, and percentage oliguric. Baseline thyroid functions,
or over short time courses at amounts ranging from twoincluding T3, T4, rT3, and thyroid stimulating hormone (TSH)
levels, were equal between the two groups and typical of pa- to five times the normal replacement doses. Neither clini-
tients with euthyroid sick syndrome. Thyroxine resulted in a cal nor laboratory evidence of hyperthyroidism was evi-
progressive and sustained suppression of TSH levels in the dent in treated animals. An uncontrolled clinical trialtreated group, but had no effect on any measure of ARF sever-
of thyroxine in a pediatric population reported that allity. Mortality was higher in the thyroxine group than the control
patients diuresed following therapy [18]. Although thy-group (43 vs. 13%) and correlated with suppression of TSH.
Conclusions. In contrast to the beneficial effects seen in roid hormone has not been tried in clinical ARF in adult
experimental ARF, thyroxine has no effect on the course of patients, several trials have reported on the use of thyroid
clinical ARF and could have a negative effect on outcome replacement in acutely ill patients [19–21]. The resultsthrough prolonged suppression of TSH. Critically ill euthyroid
of trials of thyroid hormone in the severely ill have notsick patients should not be replaced with thyroid hormone.
demonstrated a major improvement in morbidity nor
mortality in relatively small groups. The studies have
also not been able to show significant evidence of majorAcute renal failure (ARF) is a serious medical prob-
adverse effects with the use of thyroid hormone in se-lem. Despite decades of improvement in supportive care,
verely ill medical or surgical euthyroid patients. Wethe mortality of ARF in the hospitalized acutely ill pa-
therefore undertook a prospective randomized trial oftient has changed little [1–3]. In contrast to this clinical
thyroid hormone in the treatment of ARF to determinepicture, work in experimental ARF has suggested several
whether thyroid hormone altered the course or mortalitypromising therapeutic maneuvers, some of which have
associated with ARF.resulted in the amelioration or reversal of ischemic or
toxic ARF in animal models. A number of growth fac-
METHODS
The study was designed as a prospective, randomized,Key words: critical care medicine, ischemia, nephrotoxicity, thyroid
hormone, euthyroid sick syndrome. double-blind trial of thyroxine in clinical ARF. ARF was
defined as a doubling of serum creatinine within a 24-Received for publication January 15, 1999
hour period. Exclusion criteria included: (a) evidence ofand in revised form June 15, 1999
Accepted for publication September 1, 1999 reversible prerenal azotemia, defined as a fall in serum
creatinine with correction of prerenal factors, (b) renal 2000 by the International Society of Nephrology
293
Acker et al: Thyroxine therapy for ARF294
Table 1. Demographic and entry characteristicsfailure caused by urinary obstruction, (c) ARF secondary
to acute glomerulonephritis or acute interstitial nephri- Control Thyroid
tis, (d) obstetrically related ARF, (e) patients with clini- N 31 28
Age years 58.562.3 53.563cal evidence of hepatorenal syndrome, and ( f) patients
% Male 61 58with unacceptable cardiac risk, defined as New York
APACHE II 17 60.9 1861.4
Heart Class IV [22]. Patients could be removed from the % Oliguric 61 61
Creatinine (baseline) 1.160.1 1.360.1study if they developed chest pain suggestive of coronary
Creatinine (entry) 3.860.3 3.260.3ischemia, documented myocardial infarction, cardiac ar-
Data are means 6 sem. There were no significant differences between the tworhythmia associated with circulatory compromise, or evi-
groups.
dence of allergy to the study drug. No patients were
withdrawn from the study for any of these criteria. All
patients were examined prior to the entrance in the study
and appeared to be clinically euthyroid. The study was were age, sex, comorbid conditions (APACHE II), base-
approved by the Institutional Review Board for Biomed- line creatinine concentration, presence of oliguria, thy-
ical Research at the University of Pittsburgh (Pittsburgh, roid function studies, and treatment group assignment
PA, USA). Informed consent was obtained for all pa- (thyroid or control).
tients participating in the study. All patients were evaluated by the same group of
Patients were randomly assigned to receive intrave- nephrologists at the University of Pittsburgh Medical Cen-
nous thyroxine (thyroid) or placebo (control); investiga- ter (UPMC), and dialysis support was initiated for stan-
tors were blinded to the group assignment. The protocol dard indications in the setting of ARF at this institution
solution consisted of 150 mg of thyroxine in 20 mL of as previously described [25]. Renal replacement therapy
normal saline administered over five minutes by slow was either intermittent hemodialysis (HD) performed
intravenous infusion. The placebo solution consisted of with modified cellulose dialyzers, either cellulose acetate
20 mL of normal saline. Solutions were administered or hemophane, or continuous venovenous HD (CVVDH)
every 12 hours for 48 consecutive hours. The groups using polyacrilonitrile dialyzers. The choice of dialysis
were treated and monitored in the intensive care unit mode was made on clinical grounds, and CVVHD was
(ICU). At entry, demographic data, major diagnoses, primarily used for those patients who required pressor
APACHE II score [23, 24], and presence or absence of support. Some patients received both modes.
oliguria (defined as urine output ,400 mL/24 hours) Initial power analysis was carried out to ensure suffi-
were documented. Thyroid function studies [thyroid- cient power to detect differences between treatment
stimulating hormone (TSH), free T3, free T4, and reverse groups. Because the course of renal failure might be
T3 (rT3)] were obtained at study entry and on days 1, 7, influenced with or without an effect on mortality, we
and 14 after study entry. assumed that mortality was the least sensitive while also
End points of the study were patient mortality and the most reproducible outcome measure of ARF, and
severity of renal failure. These were initially examined we used this outcome for the analysis. Because a retro-
separately because of the possibility that thyroid might spective study at our institution gave an overall mortality
affect one but not the other. Patients were followed until of 60% for ICU-acquired ARF [25], the study plan was
death or discharge from the hospital. To determine if to conduct a two-sided test to determine a 33% differ-
there was a survival advantage, the percentage of survival ence in mortality (that is, a decrease in mortality to
for thyroid and control groups was compared using chi- 40%). The chi-squared test for comparing two binomial
square analysis with Yates correction. To examine the proportions was used for the analysis. The sample size
effect of thyroid on the clinical course of ARF, five determined called for 97 subjects per group [26]. During
measures of ARF severity were analyzed: (a) the percent the trial, the mortality response was monitored for early
requiring dialysis, (b) the percent recovering renal func- dramatic benefits or potential harmful effects, using the
tion, (c) the increase in serum creatinine concentration sequential method of Pocock [27]. The test statistic was
from baseline, (d) the time from initiation of ARF to computed following data acquisition of the first 60 sub-
earliest recovery (defined as increased urinary output or jects, without breaking the code by the investigators.
decline in creatine without dialysis), and (e) the time Because a significant difference in mortality was ob-
from initiation of ARF to stable recovery. Differences served at the first analysis, the trial was terminated.
in the thyroid hormone measurements in the two groups
over time were analyzed by analysis of variance supple-
RESULTSmented by a one degree of freedom t-test if the signifi-
Entry characteristics for the thyroid and control groupscance was found by analysis of variance (ANOVA).
are shown in Table 1. The groups were similar in age,Stepwise logistic regression was carried out with survival
as the dependent variable. Predictors entered stepwise sex, APACHE II scores at enrollment, the percentage
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Table 2. Etiologies of acute renal failure (ARF) higher in survivors than nonsurvivors throughout the
study and was significantly higher for survivors in bothControl Thyroid
groups at day 1. This relationship becomes clearer whenToxic 6 9
Ischemia 1 sepsis 8 6 all patients are viewed together, irrespective of group
Ischemia without sepsis 17 13 assignment (Fig. 1). The TSH level in survivors was sig-
The most likely primary etiology for ARF was estimated by clinical evaluation nificantly higher than in nonsurvivors at entry into the
of presentation. Toxic included antibiotic (primarily aminoglycoside), NSAID
study and progressively rose throughout the study. TSHtoxicity, rhabdomyolysis, and radiocontrast agents. Hypotension (ischemia) was
divided by whether or not it occurred in the presence of presumed sepsis. There levels for nonsurvivors remained quite low throughout
was no difference in frequencies of etiologies between the two groups.
the study. In an attempt to characterize this potentially
important marker further, we also compared survivors
with nonsurvivors in terms of clinical factors (Table 6).
Survivors tended to be younger, have lower APACHEwho were oliguric, and entry and baseline serum creati-
nine values. Consistent with our previous observations II scores, be less frequently oliguric, and have a less
frequent requirement for dialysis than nonsurvivors.at this institution [25], the majority of patients in both
groups received total parenteral nutrition (TPN) during However, none of these differences reached statistical
significance. Consistent with the results of the regressiontheir stay in ICU, and the use of TPN was not different
between the two groups (data not shown). Etiologies analysis, TSH at day 1 was the most robust discriminator
between survival and death.of ARF, determined during clinical evaluation of the
patients as the most likely primary cause of ARF, are Steroid and dopamine use have been reported to in-
fluence thyroid economy in critically ill patients [28, 29].listed in Table 2 for the two groups. There was no signifi-
cant difference between the two groups in terms of the We therefore examined steroid and dopamine usage in
both groups within 48 hours prior to and following studydistribution of major etiologic events for ARF. The thy-
roid function tests of the two groups are shown in Table entry. Steroid and dopamine usage were similar for both
3. At the beginning of the study (day 0), all patients groups (control 71.7%, thyroid 57.1%, P 5 NS). We also
showed the same pattern of low T4, low normal TSH compared steroid and dopamine use between survivors
levels, and elevated rT3 levels typical of the euthyroid (with rising TSH levels) and nonsurvivors (with low TSH
sick syndrome [28]. There were no significant differences levels). The use of steroids and dopamine within 48 hours
in any of these measures between the two groups at the prior to and following study entry was similar between
start of the study. The only significant changes in these survivors and nonsurvivors (Table 6). There were no
measures during the course of the study were a fall in differences between the two groups.
TSH levels in the thyroid group at days 1 and 7, and a
rise in TSH levels in the control group throughout the
DISCUSSIONstudy period. The TSH level was significantly greater in
Thyroid hormone (either T3 or T4) has been shown tocontrol compared with the thyroid group at day 7.
be active in promoting recovery from ARF in a wideOutcomes of the two groups are shown in Table 4.
variety of animal models [13–17]. A single, uncontrolledThere was no significant difference between thyroid and
trial in children suggested promising results [18]. Severalcontrol groups in any measure of severity of ARF. The
studies report the use of thyroid hormone in adults inpercentage requiring dialysis, time on dialysis, time to
ICU settings with acute nonthyroidal illness [19–21].earliest and stable recovery, and percentage of recov-
These studies were prompted by a considerable bodyering function were similar in both groups. There was a
of clinical observations suggesting abnormalities in thesignificant difference in mortality between the two
thyroid axis of the acutely ill, which have been character-groups. Mortality was significantly higher in the thyroid
ized as the euthyroid sick syndrome [28]. The hallmarksgroup. The mean time from entry to death for those who
of this syndrome are low T3, low to normal T4, elevateddied was not different between the two groups.
rT3, and normal TSH. The significance of these findingsStepwise regression analysis was undertaken to deter-
to outcome in severely ill patients is conjectural. Al-mine which clinical or laboratory characteristics best cor-
though apparently euthyroid by clinical measures, therelated with mortality. Neither age, sex, APACHE II
notion that these patients are truly euthyroid has beenscore, need for dialysis, creatinine at entry, presence
questioned [30]. The value of thyroid hormone replace-of oliguria, or group assignment (thyroid or control)
ment remains unknown [30–32], but the studies so farcorrelated significantly with survival. The only significant
performed in non-ARF patients have not shown a sig-relationship to outcome was with TSH level at day 1 of
nificant effect on outcome, either positive or negative, inthe trial. We therefore examined the relationship be-
critically ill adults. Our study demonstrates that patientstween TSH level and survival in more detail. Table 5
with ARF exhibit biochemical findings typical of thedemonstrates the TSH levels for survivors and nonsurvi-
vors at all points measured for both groups. TSH was euthyroid sick syndrome. Thyroid replacement in this
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Table 3. Thyroid hormone results
TSH (0.272–5.39 mU/mL) FT4 (0.76–1.79 ng/dL) FT3 (1.90–5.00 pg/mL) rT3 (80–350 ng/L)
Day T4Rx Control T4Rx Control T4Rx Control T4Rx Control
0 089 60.35 1.0960.31 0.73 60.10 0.71 60.03 2.49 61.55 0.84 60.05 652.326151.74 1028.376325.03
1 0.81 60.40 1.42 60.46 0.88 60.10 0.73 60.043 1.07 60.20 0.90 60.15 658.266210.78 909.5 6391.07
7 0.87 60.23a 2.7560.62b 0.7160.06 0.66 60.04 0.96 60.11 0.94 61.10 NA NA
14 2.1460.81 3.42 60.59b 0.7760.07 0.78 60.06 1.09 60.17 1.13 60.22 NA NA
Values are given as mean 6 sem.
Abbreviations are: TSH, thyroid stimulating hormone; FT4, free T4; FT3, free T3; rT3, reverse T3; NA, not assessed; T4Rx is patients treated with thyroxine.
aP 5 0.01 T4Rx vs. control
bP 5 0.02 Control day 0 vs. days 7, 14
Table 4. Outcomes
T4Rx Control
(N 5 28) (N 5 31)
SCr (peak) 5.360.5 4.6 60.5
SCr (recovery) 1.660.2 1.5 60.1
Required dialysis % 64.00 48.00
HD % 28.5 26.0
CVVHD % 10.5 3.0
Both % 25.0 19.0
Time on dialysis days 1667 11 64
Time/R1 days 964 9 63
Time/R2 days 1664 14 63
Recovery of function 15/28 20/31
Mortality 12 (43%)a 4 (13%)
Time (entry to death) days 1564 16 612
Abbreviations are: SCr (peak), maximal creatinine value; SCr (recovery), creati-
nine level at renal recovery; Time/R1, time to initial decline in serum creatinine;
Time/R2, time to stable creatinine level. Individual modalities of dialysis support
are presented as % of total group and sum to equal overall % requiring any
dialysis.
aP 5 0.01 by Fisher’s exact test
Fig. 1. Comparison of thyroid stimulating hormone (TSH) levels be-
Table 5. TSH (mU/mL) for survivors and non-survivors tween survivors (d) and nonsurvivors (j) irrespective of the group
assignment. TSH levels were significantly higher in survivors at day 1,
Control T4Rx 7, and 14. Values are presented as mean 6 sem, P , 0.05.
Day Survivors Non-survivors Survivors Non-survivors
0 1.1360.35 0.8360.58 1.32 60.63a 0.3760.10
1 1.5360.49a 0.0260.00 1.32 60.69a 0.1960.08
Table 6. Characteristics of survivors and non-survivors7 2.9760.65 0.3960.00 1.06 60.30 0.5260.31
14 3.5960.60 0.3660.00 2.61 61.00 0.5860.58
Survivors Non-survivors
aP , 0.03 survivors vs. non-survivors (N 5 43) (N 5 16)
Age 53.962.5 60.463.5
APACHE II 17.461.08 19.561.65
% Oliguric 57 69
% Dialysis 44 68euthyroid sick state in patients similarly matched for age,
Dopamine use % 48 60severity of disease, and level of renal dysfunction appears
Steroid use 30% 31%
to result in a continued suppression of TSH, as control
Data are shown as mean 6 sem or % of total per group. There were no
patients exhibited a progressive rise in TSH throughout significant differences between groups in these parameters.
the study period. Although no other clinical or biochemi-
cal evidence of hyperthyroidism was noted in our popula-
tion, the continued suppression of TSH correlated with
though the numbers are small in this study, there wasthe poorer outcome for thyroid treated patients clearly
no hint of an effect of renal failure. Along with insulin-indicates that euthyroid sick patients should not be re-
like growth factor-1 (IGF-1) [10] and atrial natriureticplaced with thyroid hormone.
peptide (ANP) [9, 12], this represents the third agentIn contrast to the remarkable effects of thyroxine on
that showed great promise in laboratory ARF but littleexperimental ARF, no effect on renal function or renal
recovery was observed in our patient population. Al- effect in clinical ARF. The possible reasons for this have
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recently been discussed [11, 33]. This study relied on in circumstances considerably more complex than exper-
changes in serum creatinine and clinical maneuvers to imental models. Our experience underscores the need
rule out prerenal states to identify true ARF. As a result, to conduct such trials with early and frequent monitoring
renal failure was established and relatively severe by the of outcomes. Finally, our results suggest that derange-
time therapy was begun. The serum creatinine was more ments in the thyroidal axis in critical illness may help to
than double the baseline values at the time of entry into predict eventual patient outcome. Sustained suppression
the study. These facts alone are not necessarily inconsis- of TSH may identify a group of patients with increased
tent with the rationale for thyroid hormone in ARF, as mortality [35].
it has been shown that thyroid is effective only after the
Reprint requests to John P. Johnson, M.D., 935 Scaife Hall, 3550insult that induces ARF and remains effective for up to Terrace Street, Pittsburgh, Pennsylvania 15213, USA.
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